Video

Pharmacist Medication Insights: for Panzyga for Primary Humoral Immunodeficiency

Author(s):

Saro Arakelians, PharmD

Panzyga is indicated for the treatment of primary humoral immunodeficiency, chronic inflammatory demyelinating polyneuropathy, and chronic immune thrombocytopenia.

Panzyga (immune globulin intravenous [Human]-ifas) is indicated for the following:

  • For the treatment of adults 18 years of age and older with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability and impairment.
  • Primary humoral immunodeficiency (PI) in patients 2 years of age and older.
  • Chronic immune thrombocytopenia (ITP) in adults.

Related Videos
Image credit: Dr_Microbe | stock.adobe.com
Image credit: komokvm | stock.adobe.com
Vial of Pneumococcal vaccine - Image credit: Bernard Chantal | stock.adobe.com
Vaccine vials used for Respiratory Syncytial Virus (RSV) with a syringe - Image credit: Peter Hansen | stock.adobe.com
Related Content
NLA 2025: Data on ApoC3 Inhibitors Shows Promise Across a Spectrum of Hypertriglyceridemic Disorders
May 31st 2025

NLA 2025: Data on ApoC3 Inhibitors Shows Promise Across a Spectrum of Hypertriglyceridemic Disorders

Alana Hippensteele, Lead Editor
Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings
May 28th 2025

Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings

Alexandra Gerlach, Associate Editor
Dry, cracked skin on finger | Image Credit: © Andriy Blokhin - stock.adobe.com
May 30th 2025

Proactive Dermatologic Care Reduces Symptom Severity and Boosts Quality of Life in NSCLC

Alexandra Gerlach, Associate Editor
pharmacy focus oncology podcast
May 19th 2025

Insights from a Pharmacy Times Peer Exchange: Real-World Outcomes and Supportive Care

Alexandra Gerlach, Associate Editor
TKIs binding to target proteins | Image Credit: © Justlight - stock.adobe.com
May 30th 2025

Patient Reported Outcomes Show Improved Symptoms With Zongertinib for HER2-Mutated Non-Small Cell Lung Cancer

Alexandra Gerlach, Associate Editor
NLA 2025: The Complementary Roles of ANGPTL3 and ANGPTL4 in Lipid Regulation and Therapy
May 30th 2025

NLA 2025: The Complementary Roles of ANGPTL3 and ANGPTL4 in Lipid Regulation and Therapy

Sander Kersten, PhD Alana Hippensteele, Lead Editor